Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Chronic hepatitis B patients not treated with antiviral drugs； Fatty liver was diagnosed by B-ultrasound and imaging； No history of excessive drinking； Good drug compliance and regular medication； Exclusion Criteria： Non chronic hepatitis B patients； Taking other drugs； liver failure, liver cancer and other diseases； patients who refused to sign informed consent；

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- The control group (Type: EXPERIMENTAL): The control group was treated with silibinin meglumine tablets and tenofovir
- The treatment group (Type: ACTIVE_COMPARATOR): The treatment group was treated with Ganshuang granules combined with silibinin meglumine tablets and tenofovir

Based on this trial design, predict the completion outcome and termination type (if applicable).